Inflammaging, metabolic syndrome and melatonin : a call for treatment studies

• Autores: Cardinali, Daniel Pedro; Hardeland, Rüdiger
• Año de publicación: 2017
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Preprint del documento publicado en Neuroendocrinology Vol. 104, N° 4, 2017; ISSN 1423-0194 (online); ISSN 0028-3835 (impreso)
• Materia: MEDICINA; MELATONINA; SINDROME METABOLICO; BIOMEDICINA; ESCLEROSIS MULTIPLE; ENVEJECIMIENTO; INFLAMACION; OBESIDAD; DIABETES; INSULINA
• Institución: Pontificia Universidad Católica Argentina

Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Hardeland, Rüdiger. University of Goettingen. Johann Friedrich Blumenbach Institute of Zoology and Anthropology; Alemania
Abstract: The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin resistance, impaired glucose tolerance and diabetes. Adipocytes secrete proinflammatory cytokines as well as leptin and trigger a vicious circle which leads to additional weight gain largely as fat. The imbalance between inflammatory and anti-inflammatory signals is crucial to aging. Healthy aging can benefit from melatonin, a compound known to possess direct and indirect antioxidant properties, to have a significant protective effect on mitochondrial function, to enhance circadian rhythm amplitudes, to modulate the immune system and to exhibit neuroprotective actions. Melatonin levels decrease in the course of senescence and are more strongly reduced in diseases related to insulin resistance. This short review article analyzes the multiple protective actions of melatonin that are relevant to the attenuation of inflammatory responses and progression of inflammaging and how melatonin is effective to curtail MS in animal models of hyperadiposity. The clinical data supporting the possible therapeutical use of melatonin in human MS are also reviewed. Since attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, piromelatine) and in clinical trials these analogs were administered in doses considerably higher than those usually employed for melatonin, clinical trials on melatonin in the range of 50-100 mg/day are needed to further assess its therapeutic value in MS.